CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL) at Sheba Medical Center
Cosa include questo pacchetto
Procedure mediche
- Terapia con cellule CAR-T
- Esami del sangue
- Esame di biochimica del sangue
- Biopsia
- TAC
- Consultazione con un medico
- Consultazione con un oncologo
- Consultazione con un ematologo
- Consultazione con un immunologo
- Consultazione con un ematologo pediatrico
- Emocromo completo con marcatori tumorali e proteinogramma
- Angiografia TC
- Elettrocardiogramma (ECG)
- Esame di follow-up
- Cura post-operatoria
- Esami preoperatori
- PET/TC
- Consultazione con un oncoematologo
- Servizi infermieristici 24 ore su 24
- 3 pasti al giorno dal nutrizionista
Durata
- 21 giorni in ospedale
Alloggio
Ospedalizzazione
Trasporto
Trasferimento aeroporto-clinica-aeroporto
Informazioni aggiuntive
CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL) at Sheba Medical Center
For patients diagnosed with Acute Lymphoblastic Leukemia (ALL), especially those with relapsed or treatment-resistant disease, access to advanced therapy can be life-changing.
Sheba Medical Center, one of the world’s leading hospitals, offers state-of-the-art CAR-T cell therapy, providing new hope where conventional treatments may no longer be effective.
Sheba is recognized as a global leader in CAR-T therapy for ALL, particularly in pediatric and young adult patients, combining cutting-edge science with extensive clinical experience.
A Faster Path to Life-Saving Treatment
At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality, critical in fast-progressing diseases like ALL.
• Apheresis – collection of the patient’s T-cells
• Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center
• Infusion – reinfusion of modified cells designed to target and eliminate leukemia cells
By keeping the entire process in-house, treatment can begin in approximately 10 days, significantly faster than many international centers.
CAR-T therapy acts as a “living drug,” continuing to work in the body and offering the potential for deep and lasting remission.
All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology.
Outstanding Outcomes That Offer Real Hope
Sheba is a world leader in pediatric CAR-T for ALL, with exceptional clinical results:
• Up to ~90% remission in pediatric patients
• ~80% in young adults (up to 23 years)
• ~70% in adult patients
These outcomes provide a powerful treatment option and a second chance for patients with limited alternatives.
Why Patients Choose Sheba
• Rapid access to CAR-T therapy – treatment initiation in ~10 days
• Extensive experience – leading CAR-T program in the region
• Dedicated CAR-T units – specialized care with 24/7 monitoring
• Multidisciplinary expertise – hematology, oncology, and immunotherapy teams working together
• Full international support – medical review, travel coordination, and patient assistance
Comprehensive, Personalized Care
Each patient undergoes a full diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and complete medical assessment, ensuring a precise, individualized treatment plan.
Services are available in English, Russian, and Arabic, providing a seamless experience for international patients and their families.
A Global Leader in Advanced Leukemia Care
By combining innovative CAR-T technology, in-house cell production, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for ALL worldwide, offering patients not just treatment, but a real opportunity for remission and renewed life.
Assistenza Bookimed 24/7
- Coordinatore medico personale
- Organizzazione dei viaggi medici — prenotazione di biglietti aerei e camere d'albergo a prezzi speciali per i partner
- Tutela degli interessi dei pazienti durante il viaggio medico
Prezzo del programma
Cosa NON include questo pacchetto
Medico
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Com'è andata la tua esperienza?
Informazioni sulla clinica
La terapia con cellule CAR T presso lo Sheba Medical Center di Tel Aviv, Israele, può costare circa $63.100 per l'intero programma. L'ospedale è tra i primi 10 al mondo e offre questo trattamento avanzato sotto la guida del Prof. Arnon Nagler, uno specialista di spicco nel trapianto di midollo osseo.
Informazioni sul Trattamento
La terapia con cellule CAR T è un approccio innovativo per leucemia, linfoma e mieloma multiplo. Essa prevede la raccolta delle cellule T del paziente, la loro modifica genetica in laboratorio e l'infusione successiva dopo la chemioterapia. Il processo richiede 21 giorni di ricovero con possibile permanenza in terapia intensiva.
Cosa è Incluso
- Valutazione completa ($5.000-$10.000)
- Raccolta delle cellule tramite aferesi ($6.600)
- Preparazione in laboratorio delle cellule modificate ($20.000)
- Condizionamento chemioterapico ($5.000)
- Ricovero di 21 giorni ($31.500)
- Valutazione post-trattamento ($3.000-$5.000)
Preparazione e Recupero
I pazienti necessitano di biopsia del midollo osseo, scansioni PET/CT e analisi del sangue prima del trattamento. Dopo l'infusione, è previsto un monitoraggio giornaliero per la sindrome da rilascio di citochine. Il soggiorno totale raccomandato in Israele è di 4-6 settimane. Si noti che la terapia CAR-T per il mieloma è ancora sperimentale.
Lo Sheba Medical Center tratta 1,5 milioni di pazienti all'anno e fornisce assistenza multilingue. È richiesto un deposito di $50.000-$60.000 prima dell'arrivo. Contattare l'ospedale per discutere se questa terapia è adatta alla vostra condizione.
Pagamenti e Benefici
I nostri servizi sono gratuiti
Il pagamento viene effettuato direttamente presso la clinica oppure tramite bonifico sul loro conto bancario ufficiale.
Alcune cliniche possono richiedere un deposito come parte della loro politica.
Paghi comodamente a rate flessibili.
Ricevi premi per raccomandare Bookimed ai tuoi amici.